Cells from people with systemic sclerosis do not properly develop into vascular smooth muscle cells when exposed to CTGF or b-FGF, which may prevent blood vessels from repairing themselves and lead to vessel narrowing.
Evidence from Studies
Supporting (1)
Community contributions welcome
Intrinsic Deregulation of Vascular Smooth Muscle and Myofibroblast Differentiation in Mesenchymal Stromal Cells from Patients with Systemic Sclerosis
Cells from people with systemic sclerosis don’t turn into the right kind of muscle cells needed to fix blood vessels when exposed to certain signals (CTGF and b-FGF), which may explain why their blood vessels keep narrowing. The study proves these cells are broken in a specific way that stops proper repair.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether impaired CTGF/b-FGF-induced VSMC differentiation in MSCs is a consistent feature across SSc subtypes and correlates with vascular complications like digital ulcers or pulmonary hypertension.
A systematic review and meta-analysis of all published studies comparing expression of SM22α, calponin, and other VSMC markers in MSCs from SSc patients versus controls after CTGF or b-FGF stimulation, with pooled effect sizes and subgroup analysis by disease subtype and vascular phenotype.
Whether restoring VSMC differentiation capacity in SSc-MSCs via targeted signaling modulation improves vascular repair in vivo.
A double-blind RCT in 80 SSc patients with digital ulcers, randomizing to autologous MSCs pre-treated ex vivo with a CTGF-enhancing agent or placebo, followed by intravenous infusion; primary outcome is time to healing of index ulcer and secondary outcomes include capillary density on nailfold videocapillaroscopy and flow-mediated dilation.
Whether the degree of impaired VSMC differentiation in baseline MSCs predicts future development of obliterative vasculopathy in early SSc.
A prospective cohort of 150 patients with early SSc (<2 years duration), collecting MSCs at baseline and measuring SM22α/calponin response to CTGF/b-FGF; primary outcome is development of new digital ulcers or pulmonary arterial hypertension over 5 years.
Whether impaired VSMC differentiation in MSCs is more pronounced in SSc patients with severe vasculopathy than in those without.
A case-control study comparing CTGF/b-FGF-induced SM22α and calponin expression in MSCs from 40 SSc patients with severe vasculopathy (≥3 digital ulcers, PAH confirmed) and 40 with minimal vascular involvement, matched for disease duration and autoantibody status.
Whether impaired VSMC differentiation in MSCs correlates with current vascular dysfunction markers in SSc patients.
A cross-sectional analysis of MSCs from 120 SSc patients, measuring SM22α and calponin expression after CTGF/b-FGF stimulation and correlating with nailfold capillary density, flow-mediated dilation, and pulmonary artery pressure measured by echocardiography.